Pelacarsen Fails to Deliver in Phase 3, Reigniting the Lp(a) Causality Debate
Start here
Pelacarsen, an antisense drug designed to lower lipoprotein(a), has fallen short in its phase 3 trial, according to an expert analysis published by JAMA Medical News on October 20, 2026. The setback has intensified the long-running dispute over whether elevated Lp(a) is a direct cause of cardiovascular disease or merely a marker of risk, a question the trial was widely expected to help settle. Attention now turns to the remaining Lp(a)-lowering agents in development, including oral and injectable candidates from other sponsors, which will face similar scrutiny over whether dramatic Lp(a) reductions translate into fewer cardiovascular events. The failure also raises questions about trial design, target populations, and the magnitude of lipid lowering needed to show clinical benefit.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- YouTubeAfter pelacarsen setback, debate over Lp(a) causality and the next pipeline
Lp(a), an LDL-like lipoprotein, is supported by epidemiologic and genetic evidence as a causal risk factor for atherosclerotic cardiovascular disease, but this has not been confirmed by outcome trials. In September 2025 Novartis announced that pelacarsen significantly lowered Lp(a) levels yet did not translate into reduced cardiovascular risk in the overall population; full results are due at the November AHA meeting. Open questions include subgroup benefit signals, event types, and dropout rates, while more potent siRNAs and oral small molecules are in late-stage trials, with readouts starting as early as 2028; guidelines keep one-time adult Lp(a) testing for risk assessment only, with no changes planned.
- JAMA NetworkPickLipoprotein(a)-Lowering Agent Fails to Reduce Cardiovascular Events
Pelacarsen did not reduce adverse cardiovascular events in a phase 3 trial despite lowering Lp(a) levels, according to the manufacturer's announcement.
Coverage and heat for this story
Reports so far 2·Heat now 15·Peak heat 16 (Oct 21 00:00)·Reports, 24h +2
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.